Insider Selling: Tandem Diabetes Care Inc (NASDAQ:TNDM) EVP Sells $944,550.00 in Stock

Tandem Diabetes Care Inc (NASDAQ:TNDM) EVP Brian B. Hansen sold 15,000 shares of the stock in a transaction on Monday, August 12th. The shares were sold at an average price of $62.97, for a total transaction of $944,550.00. Following the completion of the sale, the executive vice president now directly owns 17,991 shares in the company, valued at approximately $1,132,893.27. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

NASDAQ TNDM opened at $57.11 on Friday. The company’s 50-day moving average price is $63.64 and its 200-day moving average price is $62.33. The company has a current ratio of 2.53, a quick ratio of 2.21 and a debt-to-equity ratio of 0.11. The stock has a market cap of $3.51 billion, a PE ratio of -22.40 and a beta of 0.33. Tandem Diabetes Care Inc has a 12 month low of $26.40 and a 12 month high of $74.81.

Tandem Diabetes Care (NASDAQ:TNDM) last posted its quarterly earnings results on Thursday, August 1st. The medical device company reported ($0.03) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.23) by $0.20. The firm had revenue of $93.26 million for the quarter, compared to analysts’ expectations of $69.95 million. Tandem Diabetes Care had a negative net margin of 19.55% and a negative return on equity of 19.31%. The business’s revenue for the quarter was up 173.2% on a year-over-year basis. During the same period in the prior year, the business posted ($0.33) earnings per share. As a group, sell-side analysts forecast that Tandem Diabetes Care Inc will post -0.65 earnings per share for the current year.

Hedge funds and other institutional investors have recently bought and sold shares of the company. Nisa Investment Advisors LLC grew its holdings in shares of Tandem Diabetes Care by 53.3% in the second quarter. Nisa Investment Advisors LLC now owns 460 shares of the medical device company’s stock worth $30,000 after purchasing an additional 160 shares during the last quarter. Bremer Bank National Association bought a new position in shares of Tandem Diabetes Care in the first quarter worth about $31,000. TRUE Private Wealth Advisors bought a new position in shares of Tandem Diabetes Care in the second quarter worth about $33,000. James Investment Research Inc. grew its holdings in shares of Tandem Diabetes Care by 15.9% in the second quarter. James Investment Research Inc. now owns 1,315 shares of the medical device company’s stock worth $85,000 after purchasing an additional 180 shares during the last quarter. Finally, Stephens Inc. AR bought a new position in shares of Tandem Diabetes Care in the second quarter worth about $113,000. Hedge funds and other institutional investors own 79.75% of the company’s stock.

TNDM has been the topic of several recent analyst reports. BidaskClub raised shares of Tandem Diabetes Care from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, July 23rd. Stifel Nicolaus increased their target price on shares of Tandem Diabetes Care from $58.00 to $70.00 and gave the company a “hold” rating in a research note on Wednesday, May 1st. Leerink Swann initiated coverage on shares of Tandem Diabetes Care in a research note on Monday, May 13th. They issued an “outperform” rating and a $83.00 target price on the stock. Oppenheimer increased their target price on shares of Tandem Diabetes Care from $80.00 to $84.00 in a research note on Friday, August 2nd. Finally, Svb Leerink initiated coverage on shares of Tandem Diabetes Care in a research note on Monday, May 13th. They issued an “outperform” rating and a $83.00 target price on the stock. Four research analysts have rated the stock with a hold rating, twelve have assigned a buy rating and two have assigned a strong buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus target price of $68.38.

Tandem Diabetes Care Company Profile

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes various products for people with insulin-dependent diabetes in the United States. The company's flagship product is the t:slim X2 insulin delivery system that comprises t:slim X2 pump, its 300-unit disposable insulin cartridge, and an infusion set.

Read More: What are the benefits of buying treasury bonds?

Insider Buying and Selling by Quarter for Tandem Diabetes Care (NASDAQ:TNDM)

Receive News & Ratings for Tandem Diabetes Care Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tandem Diabetes Care and related companies with MarketBeat.com's FREE daily email newsletter.